About Gilead Sciences, Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.gilead.com
Frequently Asked Questions
What is the 52-week range for GILD?
The 52-week high is $157.29 and the 52-week low is $108.46.
What is the P/E ratio for GILD?
The P/E ratio data is currently unavailable.
What is the dividend yield for GILD?
The indicated annual dividend yield is 3.98%.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -16.30%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -10.64%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.71.
Analyst Recommendation Trends
Wall Street analyst consensus for GILD over the last few months:
Latest GILD News
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $144.74, moving 1.87% from the previous trading session.
Legend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says
Legend Biotech's (LEGN) multiple myeloma therapy Carvykti is facing growing competitive pressure as
Gilead Sciences (NASDAQ:GILD) Combines Top Technical Strength With a High-Quality Breakout Setup
Gilead Sciences (GILD) earns a 10/10 Technical Rating and 8/10 Setup Quality on ChartMill's breakout screen. See entry, stop, and risk levels.
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
Bill Clinton Sounds Alarm on HIV Funding: ‘Cheaper Medicines Mean Nothing If They Never Reach People’
Clinton warns abrupt HIV funding shifts could disrupt treatment and prevention, saying “a deadline isn’t a transition plan” and lives could be at risk.
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Molecule Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g
Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough
Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why PFE stock is a Buy.
Can Lenacapavir Power Gilead Sciences (GILD)’s Next Growth Phase?
On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study. Following […]
Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?
At first glance, Gilead Sciences, Inc. (NASDAQ:GILD) and Intuitive Surgical, Inc. (NASDAQ:ISRG) don’t make for the most obvious comparison. One sells medicines led by a massive HIV franchise, while the other has built its business around robotic surgery. Yet both have given investors a similar reason to pay attention this year, which is that growth […]
Gilead vs. Danaher: Which Healthcare Growth Story is More Convincing?
Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]
Gilead vs. Thermo Fisher: Which Life Sciences Stock has the Stronger Growth Outlook?
Gilead Sciences, Inc. (NASDAQ:GILD) and Thermo Fisher Scientific Inc. (NYSE:TMO) are benefiting from two very different sources of growth. Gilead’s momentum is being driven primarily by its HIV portfolio, where established medicines and newer products are expanding rapidly. Thermo Fisher, meanwhile, is beginning to benefit from strengthening customer activity across the life-sciences markets it serves […]
Can Gilead Sciences (GILD) Justify Its Price As It Raises 2026 Guidance And Dividend?
Gilead Sciences (GILD) has put fresh numbers on the table, raising its 2026 sales outlook and lifting its quarterly dividend by 3.8%, a combination that tends to grab investor attention. That guidance change is landing in a stock that already has momentum behind it, with a 90 day share price return of 19.46% and a year to date move of 24.12%. Over the longer haul, Gilead Sciences has delivered a 37.33% 1 year total shareholder return and triple digit total shareholder returns over 3 and 5...
Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Gilead Sciences, Inc. (NASDAQ:GILD) and Medtronic plc (NYSE:MDT) both combine growing healthcare businesses with regular cash returns to shareholders, but the sources of that growth look very different. Gilead is being propelled by its dominant HIV portfolio, where several products are expanding rapidly. On the other hand, Medtronic’s growth is spread across a much broader […]
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) both return cash to shareholders through dividends, but the businesses supporting those payouts look very different. Gilead is currently growing faster, powered by an HIV franchise that continues to gain momentum, while Abbott is offering considerably more diversification across medical devices, diagnostics, nutrition and established pharmaceuticals, as […]
Gilead or Johnson & Johnson: Is Faster Growth Better than Greater Diversification?
Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]
Gilead’s HIV Concentration or Pfizer’s Patent Cliff: Which Risk is Easier to Own?
Pfizer Inc. (NYSE:PFE) and Gilead Sciences, Inc. (NASDAQ:GILD) present investors with two very different forms of concentration risk. Pfizer needs newer medicines and its pipeline to offset revenue that will increasingly face generic and biosimilar competition, while Gilead has the opposite problem, where its biggest franchise is performing extremely well, but HIV accounts for roughly […]
Dividend Champion, Contender, And Challenger Highlights: Week September 27
Get the weekly summary of dividend changes for Dividend Champions, Contenders & Challengers, plus upcoming ex-dividend and pay dates.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
Gilead: HIV Growth Is Not Enough At The Current Price
Gilead Sciences is rated Sell, with a $97.46 fair value versus the $150.56 closing price, implying 35.3% downside. Click for more on the GILD stock.
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $152.67, moving +1.4% from the previous trading session.
1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Novo defends diversification push as CEO eyes deals beyond obesity
Novo CEO Mike Doustdar told CNBC that it is considering M&A opportunities as it faces growing competition in the weight-loss market.
BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.
Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
The drugmaker expects growth in line with industry peers as it works to rebuild its pipeline beyond obesity
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.6% on an annualized basis producing an average annual return of 16.24%. Currently, Gilead Sciences has a market capitalization of
Novo shares slide as drugmaker lays out post-Wegovy growth strategy
The Danish company seeks to convince investors it can compete in an increasingly crowded field it helped pioneer.
Why Morgan Stanley likes Gilead's HIV prevention play
After sessions with Gilead’s leadership at Morgan Stanley’s 2026 Global Healthcare Conference, the bank reaffirmed its Overweight rating, and one franchise stood out.
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
Gilead Sciences (NasdaqGS:GILD) expanded its royalty-free voluntary licensing of once-yearly lenacapavir for HIV prevention to 120 high-incidence countries. The biopharma group signed a regional agreement with the Pan American Health Organization to widen access to twice-yearly lenacapavir across Latin America and the Caribbean. The PAHO partnership creates a direct pathway for 14 additional countries in the region to obtain lenacapavir for HIV prevention programs. Gilead's broader licensing...
Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Gilead Sciences, Inc. (NASDAQ:GILD) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead’s existing voluntary […]
4 Biotech Stocks to Watch as Potential Takeover Targets
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
5 Undervalued Oncology Stocks Wall Street Is Overlooking
Oncology spending may hit $441B by 2029 as growth slows from genericsâsee 5 underappreciated cancer stocks with catalysts and upside. Click for the picks.
Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
MEXICO CITY, September 17, 2026--AIDS Healthcare Foundation (AHF), the world’s largest HIV care provider, welcomes a new agreement between Gilead Sciences and the Pan American Health Organization (PAHO) that could expand access to lenacapavir for HIV prevention in 14 countries across Latin America. The agreement represents a positive step toward expanding access in the region and a victory for civil society.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Gilead Expands Lenacapavir Access With New PAHO Deal in Latin America
GILD's PAHO deal expands twice-yearly lenacapavir access across Latin America and the Caribbean, adding 14 countries to its global access strategy.
Gilead Expands Lenacapavir Licensing Agreements to Include Once-Yearly HIV Prevention Formulation
Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
FOSTER CITY, Calif., September 16, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP). The agreements cover 120 high-incidence countries (which are primarily low- and lower-middle-income) and will support manufacturing readiness, technology transfer and future supply planning while th
Sector Update: Healthcare Stocks Ease Late Afternoon
Healthcare stocks were edging lower late Tuesday afternoon, with the NYSE Healthcare Index and the S
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances
Gilead Sciences (NASDAQ:GILD) executives outlined plans to expand the company’s HIV prevention and treatment franchises while advancing oncology and inflammation programs, with Chairman and Chief Executive Officer Dan O’Day describing the company as being at an “inflection point in value.” Speaking
Sector Update: Healthcare Stocks Lower Tuesday Afternoon
Healthcare stocks were edging down Tuesday afternoon, with the NYSE Healthcare Index fractionally lo
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
FOSTER CITY, Calif., September 15, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a new agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO Member States in Latin America and the Caribbean. Through PAHO’s Regional Revolving Funds, the agreement establishes a coordinated regional pathway to expand access to long-acting HIV prevention and support country-led eff
Gilead Sciences, Inc. (GILD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 10:45 AM EDTCompany ParticipantsDaniel O'Day -...
Gilead And PAHO Partner To Expand Twice-Yearly Lenacapavir HIV Prevention Access Across Latin America And The Caribbean
– Agreement Establishes a Regional Pathway Through PAHO’s Regional Revolving Funds to Support Country-Led Adoption of Long-Acting HIV Prevention –– Partnership Advances Gilead’s Global Access Strategy, Helping Turn
Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of Quarters
https://event.webcasts.com/starthere.jsp?ei=1776111&tp_key=7239e5582f&tp_special=8
Gilead Sciences Exec Says Weekly Oral HIV Prevention Drug Expected To Launch In Q1 2027
- conference call
Gilead Sciences Inc's Dividend Analysis
This article first appeared on GuruFocus. Gilead Sciences Inc (NASDAQ:GILD) recently announced a total dividend of $0.82 per share, with the ex-dividend date set for 2026-09-15. This upcoming distribution includes a $0.82 per share cash dividend payable on 2026-09-29.
Is Gilead Sciences (GILD) Reasonable Given Its Sales Base?
Gilead Sciences has delivered a powerful 5 year run in its share price, and fresh headlines around new research facilities and HIV treatments keep attention firmly on its growth story. With the stock now at US$146.42, the live question for investors is whether that market value lines up with what the business is generating in sales. The share price is up 146.6% over 5 years, which puts real pressure on the current sales base to justify where the stock now trades. The new Foster City research...
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.42, denoting a +1.88% move from the preceding trading day.
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
On August 13, a federal appeals court ruled in favor of Gilead Sciences, Inc. (NASDAQ:GILD), upholding a preliminary injunction that bars the defendants from importing or facilitating the sale of foreign-market Gilead-branded medications in the US. The US Court of Appeals for the Fourth Circuit found that the differences between Gilead’s HIV medication for the […]
Dividend Champion, Contender, And Challenger Highlights: Week September 13
Read this week's dividend recap for Dividend Champions, Contenders & Challengersâtrack dividend changes, upcoming ex-dividend dates & pay dates.
If You Invested $100 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.42% on an annualized basis producing an average annual return of 11.56%. Currently, Gilead Sciences has a market capitalization of
Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth
Gilead Sciences (NASDAQ:GILD) CFO Andy Dickinson told attendees at the Cantor Global Healthcare Conference that the company sees continued growth opportunities across its HIV prevention and treatment businesses, while advancing programs in inflammation, oncology and cell therapy. Dickinson said the
Gilead Sciences, Inc. (GILD) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Gilead Sciences, Inc. (GILD) 12th Annual Cantor Fitzgerald Global Healthcare Conference September 10, 2026 10:55 AM EDTCompany ParticipantsAndrew Dickinson...
Here's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
HSBC Maintains Buy on Gilead Sciences, Raises Price Target to $175
HSBC analyst Morten Herholdt maintains Gilead Sciences (NASDAQ:GILD) with a Buy and raises the price target from $155 to $175.
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat
Will The Recent Pipeline Progress Boost BMY's Portfolio Expansion?
Bristol Myers Squibb's positive arlo-cel data in heavily pretreated multiple myeloma could strengthen its cell therapy pipeline.
Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
MENLO PARK, Calif., September 09, 2026--Sofinnova Investments Announces the Appointment of Dr. Merdad Parsey as Executive Partner
1 S&P 500 Stock on Our Buy List and 2 Facing Challenges
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
Gilead launches research facility in US for new medicine development
The new research centre is part of Gilead's strategy to advance US research, development and manufacturing through 2030.
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
MacroGenics (MGNX) trades below cash with a strong ADC/TCE pipeline and ESMO 2026 catalysts.
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes – – Cash runway remains projected into 2029, including the first $75 million collaboration extension fee from Gilead payable in Q4 2026 – SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced it
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
FOSTER CITY, Calif., September 08, 2026--Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
CNBC’s Annika Kim Constantino reports on the latest news on AstraZeneca.
Bixlenvo Gives Gilead a New HIV Growth Path. How Large is the Market?
Gilead Sciences, Inc. (NASDAQ:GILD) has added another treatment to its HIV portfolio with the FDA approval of Bixlenvo, a once-daily pill for adults whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead’s (NASDAQ:GILD) blockbuster Biktarvy, and lenacapavir, the foundation of the company’s longer-term HIV strategy. […]
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence. See Exactly How Gilead, Cellectis, MediGene, GenScript, and CARsgen Are Positioned to Win Through 870+ Rivals
One-Year Analytical Tool Delivers Deal-Grade Competitive Intelligence on 2,370+ Drugs, 1,700+ BD&L Contacts, and 208 Top Investors as the Pipeline Adds 236 New Therapies in Just 12 MonthsDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Unlocking Opportunity: Dominate the Market of CAR/TCR/TIL Therapies in Oncology with Confidence" directory has been added to ResearchAndMarkets.com's offering. The world of CAR/TCR/TIL therapies is transforming cancer treatment, unlocking new levels of precision, i
Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?
Gilead Sciences is branching out beyond its HIV franchise into oncology and immunology therapies.
Will New HIV and Oncology Approvals Redefine Gilead Sciences' (GILD) Treatment Platform Narrative?
Gilead Sciences recently secured U.S. FDA approval for Bixlenvo, a once-daily single tablet regimen for virologically suppressed adults with HIV on complex regimens, and European Commission approval for Trodelvy plus Keytruda as a first-line treatment for certain PD-L1–positive metastatic triple-negative breast cancer patients. These back-to-back approvals broaden Gilead’s reach in HIV and oncology by addressing hard-to-treat, heavily pretreated populations with simplified or first-in-class...
Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue?
Kymera Therapeutics (KYMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out. Here is what that risk actually means for income investors counting on the check.
Gilead Sciences (NASDAQ:GILD): A Quality Dividend Stock for Income Investors
Gilead Sciences offers a 3.98% dividend yield backed by strong profitability and a solid track record, meeting key quality, health, and income criteria.
Gilead’s growing HIV franchise; cell therapy licensing deals plummet
The FDA recently OK'd Gilead's novel HIV combo med, and cell therapy deals have fallen dramatically in two years.
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Gilead Sciences Stock Outperforming the S&P 500?
Gilead Sciences has rallied the S&P 500 Index over the past year, and analysts remain highly bullish about the stock’s growth prospects.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Burkhart Erin | -2,223 | - | - |
| 2026-09-22 | Burkhart Erin | -768 | $152.67 | $117,251 |
| 2026-09-22 | Burkhart Erin | +2,223 | - | - |
| 2026-09-15 | Mercier Johanna | -600 | $145.29 | $87,174 |
| 2026-09-15 | Mercier Johanna | -800 | $144.4569 | $115,566 |
| 2026-09-15 | Mercier Johanna | -1,600 | $143.6917 | $229,907 |
| 2026-09-15 | Dickinson Andrew D | -3,000 | $145.29 | $435,870 |
| 2026-09-10 | Cain Wettan Keeley M | -590 | - | - |
| 2026-09-10 | Cain Wettan Keeley M | -285 | $144.81 | $41,271 |
| 2026-09-10 | Cain Wettan Keeley M | +590 | - | - |
| 2026-09-10 | Mercier Johanna | -2,797 | - | - |
| 2026-09-10 | Mercier Johanna | -1,347 | $144.81 | $195,059 |
| 2026-09-10 | Mercier Johanna | +2,797 | - | - |
| 2026-09-10 | Berger Dietmar | -533 | - | - |
| 2026-09-10 | Berger Dietmar | -263 | $144.81 | $38,085 |
| 2026-09-10 | Berger Dietmar | +533 | - | - |
| 2026-09-10 | O'Day Daniel Patrick | -8,780 | - | - |
| 2026-09-10 | O'Day Daniel Patrick | -4,230 | $144.81 | $612,546 |
| 2026-09-10 | O'Day Daniel Patrick | +8,780 | - | - |
| 2026-09-10 | Dickinson Andrew D | -2,797 | - | - |
| 2026-09-10 | Dickinson Andrew D | -1,347 | $144.81 | $195,059 |
| 2026-09-10 | Dickinson Andrew D | +2,797 | - | - |
| 2026-09-01 | O'Day Daniel Patrick | -5,408 | $149.3817 | $807,856 |
| 2026-09-01 | O'Day Daniel Patrick | -7,992 | $148.3636 | $1,185,722 |
| 2026-09-01 | O'Day Daniel Patrick | -1,600 | $147.5087 | $236,014 |
| 2026-08-26 | WELTERS ANTHONY | -10,282 | - | - |
| 2026-08-26 | WELTERS ANTHONY | -7,718 | - | - |
| 2026-08-26 | WELTERS ANTHONY | -6,880 | $148.8227 | $1,023,900 |
| 2026-08-26 | WELTERS ANTHONY | -3,402 | $148.2353 | $504,296 |
| 2026-08-26 | WELTERS ANTHONY | +10,282 | $61.35 | $630,801 |
| 2026-08-26 | WELTERS ANTHONY | -4,600 | $148.824 | $684,590 |
| 2026-08-26 | WELTERS ANTHONY | -3,118 | $148.3106 | $462,432 |
| 2026-08-26 | WELTERS ANTHONY | +7,718 | $60.67 | $468,251 |
| 2026-08-20 | Bluestone Jeffrey | -335 | - | - |
| 2026-08-20 | Bluestone Jeffrey | -4,665 | - | - |
| 2026-08-20 | Bluestone Jeffrey | -335 | $146.26 | $48,997 |
| 2026-08-20 | Bluestone Jeffrey | +335 | $61.35 | $20,552 |
| 2026-08-20 | Bluestone Jeffrey | -26 | $146.36 | $3,805 |
| 2026-08-20 | Bluestone Jeffrey | +26 | $67.45 | $1,754 |
| 2026-08-20 | Bluestone Jeffrey | -1,658 | $145.7286 | $241,618 |
| 2026-08-20 | Bluestone Jeffrey | +1,658 | $67.45 | $111,832 |
| 2026-08-20 | Bluestone Jeffrey | -1,816 | $144.9248 | $263,183 |
| 2026-08-20 | Bluestone Jeffrey | +1,816 | $67.45 | $122,489 |
| 2026-08-20 | Bluestone Jeffrey | -1,165 | $143.7543 | $167,474 |
| 2026-08-20 | Bluestone Jeffrey | +1,165 | $67.45 | $78,579 |
| 2026-08-17 | Mercier Johanna | -1,890 | - | - |
| 2026-08-17 | Mercier Johanna | -23,110 | - | - |
| 2026-08-17 | Mercier Johanna | -11,470 | $138.0353 | $1,583,265 |
| 2026-08-17 | Mercier Johanna | -16,530 | $137.365 | $2,270,643 |
| 2026-08-17 | Mercier Johanna | +1,890 | $72.34 | $136,723 |
| 2026-08-17 | Mercier Johanna | +23,110 | $66.64 | $1,540,050 |
| 2026-08-17 | Dickinson Andrew D | -3,000 | $138.36 | $415,080 |
| 2026-08-10 | Cain Wettan Keeley M | -6,002 | - | - |
| 2026-08-10 | Cain Wettan Keeley M | -2,908 | $133.06 | $386,938 |
| 2026-08-10 | Cain Wettan Keeley M | +6,002 | - | - |
| 2026-08-03 | O'Day Daniel Patrick | -600 | $131.3433 | $78,806 |
| 2026-08-03 | O'Day Daniel Patrick | -7,700 | $130.8022 | $1,007,177 |
| 2026-08-03 | O'Day Daniel Patrick | -6,700 | $129.6583 | $868,711 |
| 2026-07-15 | Mercier Johanna | -3,000 | $129.9192 | $389,758 |
| 2026-07-15 | Dickinson Andrew D | -3,000 | $129.9256 | $389,777 |
| 2026-07-01 | O'Day Daniel Patrick | -3,100 | $127.075 | $393,933 |
| 2026-07-01 | O'Day Daniel Patrick | -11,900 | $126.0897 | $1,500,467 |
| 2026-06-15 | Mercier Johanna | -450 | $125.4 | $56,430 |
| 2026-06-15 | Mercier Johanna | -1,070 | $123.9958 | $132,676 |
| 2026-06-15 | Mercier Johanna | -1,480 | $123.4166 | $182,657 |
| 2026-06-15 | Dickinson Andrew D | -3,000 | $125.4 | $376,200 |
| 2026-06-10 | Cain Wettan Keeley M | -589 | - | - |
| 2026-06-10 | Cain Wettan Keeley M | -283 | $121.48 | $34,379 |
| 2026-06-10 | Cain Wettan Keeley M | +589 | - | - |
| 2026-06-10 | Mercier Johanna | -2,796 | - | - |
| 2026-06-10 | Mercier Johanna | -1,341 | $121.48 | $162,905 |
| 2026-06-10 | Mercier Johanna | +2,796 | - | - |
| 2026-06-10 | Berger Dietmar | -533 | - | - |
| 2026-06-10 | Berger Dietmar | -263 | $121.48 | $31,949 |
| 2026-06-10 | Berger Dietmar | +533 | - | - |
| 2026-06-10 | O'Day Daniel Patrick | -8,779 | - | - |
| 2026-06-10 | O'Day Daniel Patrick | -4,213 | $121.48 | $511,795 |
| 2026-06-10 | O'Day Daniel Patrick | +8,779 | - | - |
| 2026-06-10 | Dickinson Andrew D | -2,796 | - | - |
| 2026-06-10 | Dickinson Andrew D | -1,341 | $121.48 | $162,905 |
| 2026-06-10 | Dickinson Andrew D | +2,796 | - | - |
| 2026-06-01 | O'Day Daniel Patrick | -1,038 | $132.9678 | $138,021 |
| 2026-06-01 | O'Day Daniel Patrick | -3,062 | $132.2151 | $404,843 |
| 2026-06-01 | O'Day Daniel Patrick | -10,900 | $131.0994 | $1,428,983 |
| 2026-05-15 | Mercier Johanna | -25,000 | - | - |
| 2026-05-15 | Mercier Johanna | -700 | $132.7514 | $92,926 |
| 2026-05-15 | Mercier Johanna | -8,374 | $132.2324 | $1,107,314 |
| 2026-05-15 | Mercier Johanna | -11,177 | $131.1917 | $1,466,330 |
| 2026-05-15 | Mercier Johanna | -7,749 | $130.2915 | $1,009,629 |
| 2026-05-15 | Mercier Johanna | +25,000 | $66.64 | $1,666,000 |
| 2026-05-15 | Dickinson Andrew D | -3,000 | $132.27 | $396,810 |
| 2026-04-30 | Bluestone Jeffrey | +4,884 | - | - |
| 2026-04-30 | Bluestone Jeffrey | +1,146 | - | - |
| 2026-04-30 | Horning Sandra | +4,884 | - | - |
| 2026-04-30 | Horning Sandra | +1,146 | - | - |
| 2026-04-30 | Kramer Kelly A. | +4,884 | - | - |
| 2026-04-30 | Kramer Kelly A. | +1,146 | - | - |
| 2026-04-30 | MANWANI HARISH | +4,884 | - | - |
| 2026-04-30 | MANWANI HARISH | -224 | $130.84 | $29,308 |
| 2026-04-30 | MANWANI HARISH | +1,146 | - | - |
| 2026-04-30 | Rodriguez Javier | +4,884 | - | - |
| 2026-04-30 | Rodriguez Javier | +1,146 | - | - |
| 2026-04-30 | WELTERS ANTHONY | +4,884 | - | - |
| 2026-04-30 | WELTERS ANTHONY | +1,146 | - | - |
| 2026-04-30 | LOVE TED W | +4,884 | - | - |
| 2026-04-30 | LOVE TED W | +1,146 | - | - |
| 2026-04-30 | BARTON JACQUELINE K | +4,884 | - | - |
| 2026-04-30 | BARTON JACQUELINE K | +1,146 | - | - |
| 2026-04-28 | O'Day Daniel Patrick | -3,050 | $130.0111 | $396,534 |
| 2026-04-28 | O'Day Daniel Patrick | -6,950 | $128.7877 | $895,075 |
| 2026-04-15 | Mercier Johanna | -3,000 | $140.96 | $422,880 |
| 2026-04-15 | Dickinson Andrew D | -3,000 | $140.96 | $422,880 |
| 2026-03-27 | O'Day Daniel Patrick | -10,000 | $136.8162 | $1,368,162 |
| 2026-03-16 | Mercier Johanna | -3,000 | $144.23 | $432,690 |
| 2026-03-16 | Dickinson Andrew D | -3,000 | $144.23 | $432,690 |
| 2026-03-10 | Mercier Johanna | +35,880 | - | - |
| 2026-03-10 | Mercier Johanna | +9,590 | - | - |
| 2026-03-10 | Mercier Johanna | -6,617 | - | - |
| 2026-03-10 | Mercier Johanna | -3,216 | $148.56 | $477,769 |
| 2026-03-10 | Mercier Johanna | +6,617 | - | - |
| 2026-03-10 | Dickinson Andrew D | +35,880 | - | - |
| 2026-03-10 | Dickinson Andrew D | +9,590 | - | - |
| 2026-03-10 | Dickinson Andrew D | -6,469 | - | - |
| 2026-03-10 | Dickinson Andrew D | -3,147 | $148.56 | $467,518 |
| 2026-03-10 | Dickinson Andrew D | +6,469 | - | - |
| 2026-03-10 | Cain Wettan Keeley M | +18,885 | - | - |
| 2026-03-10 | Cain Wettan Keeley M | +5,050 | - | - |
| 2026-03-10 | Cain Wettan Keeley M | -1,246 | - | - |
| 2026-03-10 | Cain Wettan Keeley M | -606 | $148.56 | $90,027 |
| 2026-03-10 | Cain Wettan Keeley M | +1,246 | - | - |
| 2026-03-10 | Burkhart Erin | +5,455 | - | - |
| 2026-03-10 | Burkhart Erin | +2,355 | - | - |
| 2026-03-10 | Berger Dietmar | +31,475 | - | - |
| 2026-03-10 | Berger Dietmar | +8,415 | - | - |
| 2026-03-10 | Berger Dietmar | -2,133 | - | - |
| 2026-03-10 | Berger Dietmar | -1,063 | $148.56 | $157,919 |
| 2026-03-10 | Berger Dietmar | +2,133 | - | - |
| 2026-03-10 | O'Day Daniel Patrick | +122,755 | - | - |
| 2026-03-10 | O'Day Daniel Patrick | +32,815 | - | - |
| 2026-03-10 | O'Day Daniel Patrick | -20,026 | - | - |
| 2026-03-10 | O'Day Daniel Patrick | -9,767 | $148.56 | $1,450,986 |
| 2026-03-10 | O'Day Daniel Patrick | +20,026 | - | - |
| 2026-02-27 | Mercier Johanna | +11,090 | - | - |
| 2026-02-27 | Dickinson Andrew D | +11,090 | - | - |
| 2026-02-27 | Cain Wettan Keeley M | +470 | - | - |
| 2026-02-27 | Berger Dietmar | +8,530 | - | - |
| 2026-02-27 | O'Day Daniel Patrick | -100 | $145.71 | $14,571 |
| 2026-02-27 | O'Day Daniel Patrick | -6,419 | $145.1786 | $931,901 |
| 2026-02-27 | O'Day Daniel Patrick | -3,481 | $144.0351 | $501,386 |
| 2026-02-27 | O'Day Daniel Patrick | +38,396 | - | - |
| 2026-02-17 | Mercier Johanna | -25,000 | - | - |
| 2026-02-17 | Mercier Johanna | -200 | $155.62 | $31,124 |
| 2026-02-17 | Mercier Johanna | -9,395 | $154.9105 | $1,455,384 |
| 2026-02-17 | Mercier Johanna | -18,405 | $154.182 | $2,837,720 |
| 2026-02-17 | Mercier Johanna | +25,000 | $66.64 | $1,666,000 |
| 2026-02-17 | Dickinson Andrew D | -3,000 | $154.43 | $463,290 |
| 2026-02-05 | O'Day Daniel Patrick | -115,640 | - | - |
| 2026-02-05 | O'Day Daniel Patrick | -115,640 | $150 | $17,346,000 |
| 2026-02-05 | O'Day Daniel Patrick | +115,640 | $66.01 | $7,633,396 |
| 2026-02-03 | Mercier Johanna | -24,800 | $143.28 | $3,553,344 |
| 2026-02-03 | Mercier Johanna | +44,867 | - | - |
| 2026-02-03 | O'Day Daniel Patrick | -74,461 | $143.28 | $10,668,772 |
| 2026-02-03 | O'Day Daniel Patrick | +131,675 | - | - |
| 2026-02-03 | Dickinson Andrew D | -24,802 | $143.28 | $3,553,631 |
| 2026-02-03 | Dickinson Andrew D | +44,867 | - | - |
| 2026-01-28 | O'Day Daniel Patrick | -4,968 | $140.2426 | $696,725 |
| 2026-01-28 | O'Day Daniel Patrick | -5,032 | $139.5441 | $702,186 |
| 2026-01-23 | O'Day Daniel Patrick | -115,640 | - | - |
| 2026-01-23 | O'Day Daniel Patrick | -115,640 | $135 | $15,611,400 |
| 2026-01-23 | O'Day Daniel Patrick | +115,640 | $66.01 | $7,633,396 |
| 2026-01-20 | Bluestone Jeffrey | -5,000 | - | - |
| 2026-01-20 | Bluestone Jeffrey | -5,000 | $123.5 | $617,500 |
| 2026-01-20 | Bluestone Jeffrey | +5,000 | $67.45 | $337,250 |
| 2026-01-15 | Mercier Johanna | -3,000 | $124.31 | $372,930 |
| 2026-01-15 | Dickinson Andrew D | -3,000 | $124.31 | $372,930 |
| 2026-01-02 | Berger Dietmar | -16,326 | - | - |
| 2026-01-02 | Berger Dietmar | -6,944 | $121.6 | $844,390 |
| 2026-01-02 | Berger Dietmar | +16,326 | - | - |
| 2025-12-29 | O'Day Daniel Patrick | -10,000 | $124.8272 | $1,248,272 |
| 2025-12-15 | Mercier Johanna | -3,000 | $122 | $366,000 |
| 2025-12-15 | Dickinson Andrew D | -3,000 | $122 | $366,000 |
| 2025-12-10 | Mercier Johanna | -3,842 | - | - |
| 2025-12-10 | Mercier Johanna | -1,814 | $121.34 | $220,111 |
| 2025-12-10 | Mercier Johanna | +3,842 | - | - |
| 2025-12-10 | O'Day Daniel Patrick | -10,426 | - | - |
| 2025-12-10 | O'Day Daniel Patrick | -4,931 | $121.34 | $598,328 |
| 2025-12-10 | O'Day Daniel Patrick | +10,426 | - | - |
| 2025-12-10 | Dickinson Andrew D | -3,693 | - | - |
| 2025-12-10 | Dickinson Andrew D | -1,745 | $121.34 | $211,738 |
| 2025-12-10 | Dickinson Andrew D | +3,693 | - | - |
| 2025-11-28 | Bluestone Jeffrey | -5,000 | - | - |
| 2025-11-28 | Bluestone Jeffrey | -5,000 | $125.08 | $625,400 |
| 2025-11-28 | Bluestone Jeffrey | +5,000 | $64.92 | $324,600 |
| 2025-11-28 | O'Day Daniel Patrick | -6,788 | $126.8438 | $861,016 |
| 2025-11-28 | O'Day Daniel Patrick | -3,212 | $125.9116 | $404,428 |
| 2025-11-28 | Kramer Kelly A. | -2,805 | - | - |
| 2025-11-28 | Kramer Kelly A. | -2,805 | $127.1 | $356,516 |
| 2025-11-28 | Kramer Kelly A. | +2,805 | $81 | $227,205 |
| 2025-11-26 | Kramer Kelly A. | -2,806 | - | - |
| 2025-11-26 | Kramer Kelly A. | -2,806 | $127.11 | $356,671 |
| 2025-11-26 | Kramer Kelly A. | +2,806 | $81 | $227,286 |
| 2025-11-17 | Mercier Johanna | -25,000 | - | - |
| 2025-11-17 | Mercier Johanna | -2,476 | $126.2575 | $312,614 |
| 2025-11-17 | Mercier Johanna | -25,524 | $125.8251 | $3,211,560 |
| 2025-11-17 | Mercier Johanna | +25,000 | $66.64 | $1,666,000 |
| 2025-11-17 | Dickinson Andrew D | -2,500 | $125.23 | $313,075 |
| 2025-11-12 | Telman Deborah H | -500 | - | - |
| 2025-11-12 | Telman Deborah H | -35,965 | - | - |
| 2025-11-12 | Telman Deborah H | -17,181 | - | - |
| 2025-11-12 | Telman Deborah H | -500 | $122.904 | $61,452 |
| 2025-11-12 | Telman Deborah H | +500 | $60.75 | $30,375 |
| 2025-11-12 | Telman Deborah H | -35,965 | $122.302 | $4,398,591 |
| 2025-11-12 | Telman Deborah H | +35,965 | $60.75 | $2,184,874 |
| 2025-11-12 | Telman Deborah H | -17,181 | $124 | $2,130,444 |
| 2025-11-12 | Telman Deborah H | +17,181 | $75.12 | $1,290,637 |
| 2025-10-28 | O'Day Daniel Patrick | -2,022 | $118.8223 | $240,259 |
| 2025-10-28 | O'Day Daniel Patrick | -7,978 | $119.5371 | $953,667 |
| 2025-10-25 | Telman Deborah H | -515 | - | - |
| 2025-10-25 | Telman Deborah H | -241 | $120.94 | $29,147 |
| 2025-10-25 | Telman Deborah H | +515 | - | - |
| 2025-10-15 | Mercier Johanna | -3,000 | $118.08 | $354,240 |
| 2025-10-15 | Dickinson Andrew D | -2,500 | $118.08 | $295,200 |